Netarsudil is a Rho kinase inhibitor, works at the cellular level within the trabecular outflow pathway to relax actin-myosin. This causes relaxation within the trabecular meshwork and the inner wall of Schlemm's canal and decreases episcleral venous pressure (EVP).

Netarsudil ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

The recommended dosage is one drop in the affected eye(s) once daily in the evening.

The most common ocular adverse reaction observed in controlled clinical studies with Netarsudil was conjunctival hyperemia, corneal verticillata, instillation site pain, corneal staining and blurred vision.

For ophthalmic use only. To avoid possible contamination of the drops, do not touch the dropper tip or to any surface. Netarsudil can be used with other topical eye drug products, but they should be administered at least 5 minutes apart from each other. Contact lenses should be removed prior to instillation of Netarsudil and may be reinserted 15 minutes following its administration.

Pregnancy & Lactation

Pregnancy: There are no adequate and well-controlled studies of Netarsudil ophthalmic solution in pregnant women to inform any drug-associated risk. However, systemic exposure to Netarsudil from ocular administration is low.

Lactation: There are no data on the presence of Netarsudil in human milk, the effects on the breastfed infant, or the effects on milk production.

Pediatric Use: Safety and effectiveness in pediatric patients below the age of 18 years have not been established.

Use in elderly patients: No overall differences in safety and effectiveness have been observed between elderly and other adult patients.